BioSpace News Archive

NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets.

Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, was named as winner in the Telehealth Innovation category at the University of California San Francisco (UCSF) Health Hub Digital Health Awards, at the 2022 HLTH conference.

Simcere Pharmaceutical Group Ltd (2096.HK, “Simcere”) and Idorsia Ltd (SIX: IDIA, “Idorsia”), specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options, announced today that they have entered into an exclusive licensing agreement for Idorsia’s daridorexant in China.

CANbridge Pharmaceuticals, Inc. (1228.HK) announced that CAN106, a clinical-stage recombinant humanized monoclonal antibody targeting C5, has been granted Orphan Drug Designation by the United States Food and Drug administration (FDA) for the treatment of myasthenia gravis (MG), an autoimmune neuromuscular disease that causes weakness in skeletal muscles.

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2022.

Novocure announced it has opened a new office in Montreal to expand and support its growing business in Canada.

Simulations Plus, Inc today announced that, through a joint proposal with the University of Bath’s Department of Life Sciences, it has been awarded a new funded grant from the U.S. Food and Drug Administration.

BioCorRx Inc., a developer and provider of innovative treatment programs for substance abuse and related disorders, provided a business update for the third quarter ended September 30, 2022 and reported on recent corporate developments.

CardieX Limited, a global health technology company focused on cardiovascular disease, announced that it has acquired all the assets of Blumio, Inc., a Silicon Valley based developer of advanced algorithms and technology for cardiovascular sensors, signifying the company’s continued investment in cardiovascular health monitoring technologies.

NeuroQuest, a company focused on the discovery of blood-based immune biomarkers in pre-clinical stage Alzheimer’s, announced that together with the Australian Imaging, Biomarker & Lifestyle Flagship Study (AIBL), it has completed a clinical study demonstrating that specific immune deficits that are associated with the development of Alzheimer’s disease may be identified.